Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population

被引：1

作者：

Fujiwara, Ryo ^{[1
]}

Yuasa, Takeshi ^{[1
,3
]}

Kobayashi, Kenichi ^{[2
]}

Yoshida, Tetsuya ^{[2
]}

Kageyama, Susumu ^{[2
]}

机构：

[1] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Urol, Tokyo, Japan

[2] Shiga Univ Med Sci, Dept Urol, Seta, Otsu, Japan

[3] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Urol, Tokyo 1358550, Japan

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2023年 / 23卷 / 05期

关键词：

Immune checkpoint inhibitor (ICI); tyrosine kinase inhibitor (TKI); combination therapy; pembrolizumab plus lenvatinib; metastatic renal cell cancer (mRCC); interpatient heterogeneity; HEPATOCELLULAR-CARCINOMA; TARGETED THERAPY; INTERFERON-ALPHA; SUNITINIB; PHASE-3; SORAFENIB; CABOZANTINIB; MANAGEMENT; CONSENSUS; EFFICACY;

D O I：

10.1080/14737140.2023.2200170

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: At present, the combination of immune checkpoint inhibitors (ICIs) or an ICI and a tyrosine kinase inhibitor (TKI) are the main treatment options as first-line therapy for metastatic renal cell cancer (mRCC). Among them, pembrolizumab plus lenvatinib was recently launched in Japanese clinical practice.Area covered: In this review, the efficacies and safety profiles of pembrolizumab plus lenvatinib for mRCC between Japanese and global populations are compared. In addition, lenvatinib is currently available for the treatment of not only mRCC but also of endometrial, thyroid, thymic, and hepatocellular cancers. We briefly summarized the characteristics of pembrolizumab plus lenvatinib or lenvatinib monotherapy for these malignancies. Finally, the characteristics of pembrolizumab plus lenvatinib for mRCC in the Japanese population are briefly elucidated.Expert opinion: In order to develop optimal personalized treatment for mRCC patients, it is necessary for physicians who treat mRCC patients to possess in-depth knowledge of not only the efficacy and safety profile of the respective therapies but also of the interpatient heterogeneities between Japanese and global populations.

引用

页码：461 / 469

页数：9

共 41 条

[1] Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society [J].

Arima, Hiroshi ;

Iwama, Shintaro ;

Inaba, Hidefumi ;

Ariyasu, Hiroyuki ;

Makita, Noriko ;

Otsuki, Michio ;

Kageyama, Kazunori ;

Imagawa, Akihisa ;

Akamizu, Takashi .

ENDOCRINE JOURNAL, 2019, 66 (07) :581-586

[2] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Powles, T. ;

Burotto, M. ;

Escudier, B. ;

Bourlon, M. T. ;

Zurawski, B. ;

Juarez, V. M. Oyervides ;

Hsieh, J. J. ;

Basso, U. ;

Shah, A. Y. ;

Suarez, C. ;

Hamzaj, A. ;

Goh, J. C. ;

Barrios, C. ;

Richardet, M. ;

Porta, C. ;

Kowalyszyn, R. ;

Feregrino, J. P. ;

Zolnierek, J. ;

Pook, D. ;

Kessler, E. R. ;

Tomita, Y. ;

Mizuno, R. ;

Bedke, J. ;

Zhang, J. ;

Maurer, M. A. ;

Simsek, B. ;

Ejzykowicz, F. ;

Schwab, G. M. ;

Apolo, A. B. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841

[3] Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis [J].

Choueiri, Toni K. ;

Bauer, Todd M. ;

Papadopoulos, Kyriakos P. ;

Plimack, Elizabeth R. ;

Merchan, Jaime R. ;

McDermott, David F. ;

Michaelson, M. Dror ;

Appleman, Leonard J. ;

Thamake, Sanjay ;

Perini, Rodolfo F. ;

Zojwalla, Naseem J. ;

Jonasch, Eric .

NATURE MEDICINE, 2021, 27 (05) :802-+

[4] Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial [J].

Choueiri, Toni K. ;

Halabi, Susan ;

Sanford, Ben L. ;

Hahn, Olwen ;

Michaelson, M. Dror ;

Walsh, Meghara K. ;

Feldman, Darren R. ;

Olencki, Thomas ;

Picus, Joel ;

Small, Eric J. ;

Dakhil, Shaker ;

George, Daniel J. ;

Morris, Michael J. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) :591-+

[5] Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma [J].

Ernst, Matthew S. ;

Navani, Vishal ;

Wells, J. Connor ;

Donskov, Frede ;

Basappa, Naveen ;

Labaki, Chris ;

Pal, Sumanta K. ;

Meza, Luis ;

Wood, Lori A. ;

Ernst, D. Scott ;

Szabados, Bernadett ;

McKay, Rana R. ;

Parnis, Francis ;

Suarez, Cristina ;

Yuasa, Takeshi ;

Lalani, Aly-Khan ;

Alva, Ajjai ;

Bjarnason, Georg A. ;

Choueiri, Toni K. ;

Heng, Daniel Y. C. .

EUROPEAN UROLOGY, 2023, 84 (01) :109-116

[6] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[7] Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study [J].

Eto, Masatoshi ;

Takagi, Toshio ;

Kimura, Go ;

Fukasawa, Satoshi ;

Tamada, Satoshi ;

Miura, Yuji ;

Oya, Mototsugu ;

Sassa, Naoto ;

Anai, Satoshi ;

Nozawa, Masahiro ;

Sakai, Hideki ;

Perini, Rodolfo ;

Yusa, Wataru ;

Ikezawa, Hiroki ;

Narita, Tomoyuki ;

Tomita, Yoshihiko .

CANCER MEDICINE, 2023, 12 (06) :6902-6912

[8] Palmar-Plantar Erythrodysesthesia Associated with Chemotherapy and Its Treatment [J].

Farr, Katherina Podlekareva ;

Safwat, Akmal .

CASE REPORTS IN ONCOLOGY, 2011, 4 (01) :229-235

[9] Developments in personalized therapy for metastatic renal cell carcinoma [J].

Fujiwara, Ryo ;

Kageyama, Susumu ;

Yuasa, Takeshi .

EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (06) :647-655

[10] Prognostic significance of 8 weeks' relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients [J].

Fukuda, Naoki ;

Toda, Kazuhisa ;

Wang, Xiaofei ;

Ohmoto, Akihiro ;

Hayashi, Naomi ;

Urasaki, Tetsuya ;

Sato, Yasuyoshi ;

Nakano, Kenji ;

Ono, Makiko ;

Tomomatsu, Junichi ;

Mitani, Hiroki ;

Takahashi, Shunji .

ENDOCRINE JOURNAL, 2021, 68 (06) :639-647

← 1 2 3 4 5 →